AVITA Medical Announces September Investor Conference Participation and Fireside Chat with Morgan Stanley

AVITA Medical will participate in three investor conferences in September 2025, with key executives presenting at each event. A live audio webcast of the Morgan Stanley fireside chat will be available on the company's website for 90 days. The company's transformative wound care technologies, including the RECELL System, will be highlighted during the presentations.

AVITA Medical, Inc. (NASDAQ: RCEL), a leading therapeutic acute wound care company, has announced its participation in three major investor conferences this September. The company's management will engage in the following events:

1. Cantor Global Healthcare Conference on September 4, featuring a fireside chat with CFO David O'Toole.
2. Morgan Stanley Global Healthcare Conference on September 8, with CEO Jim Corbett.
3. Lake Street Capital Markets Best Ideas Growth Conference on September 11, with CFO David O'Toole.

The Morgan Stanley fireside chat will be available via webcast for 90 days on AVITA Medical's investor relations website.

AVITA Medical's participation in these conferences comes as the company aims to highlight its transformative wound care technologies, including the RECELL® System. The RECELL System, approved by the FDA for the treatment of thermal burn and trauma wounds, harnesses the healing properties of a patient's own skin to create Spray-On Skin™ Cells. This innovative solution offers an effective solution for improved clinical outcomes at the point-of-care.

In addition to the RECELL System, AVITA Medical also holds exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix. These products are designed to optimize wound healing and accelerate patient recovery.

AVITA Medical's international presence is also significant. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan. The company's commitment to innovation and patient care is evident in its participation in these investor conferences.

For more information, visit [AVITA Medical's website](https://www.avitamedical.com).

References:
[1] https://www.stocktitan.net/news/RCEL/avita-medical-announces-september-investor-conference-ymrkm3032tdh.html